Shuchao C. Qin

Nanjing, 210029, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Long-term outcomes of first-line iFCR regimen in chronic lymphocytic leukemia/small lymphocytic lymphoma and the role of MRD

Long-term outcomes of first-line iFCR regimen in chronic lymphocytic leukemia/small lymphocytic lymphoma and the role of MRD

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: May 20, 2026

Bendamustine combined with anti-CD20 monoclonal antibody in the first-line treatment of older patients with indolent B-cell non-Hodgkin lymphoma: a multicenter retrospective study

Bendamustine combined with anti-CD20 monoclonal antibody in the first-line treatment of older patients with indolent B-cell non-Hodgkin lymphoma: a multicenter retrospective study

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: October 27, 2025

Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial).

Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial).

Journal: Journal of the National Cancer Center

Published: September 08, 2025

Efficacy and safety of orelabrutinib combined with rituximab and high dose methotrexate in primary or secondary central nervous system diffuse large B-cell lymphoma: a retrospective analysis.

Efficacy and safety of orelabrutinib combined with rituximab and high dose methotrexate in primary or secondary central nervous system diffuse large B-cell lymphoma: a retrospective analysis.

Journal: Investigational new drugs

Published: March 10, 2025

Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non-germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG).

Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non-germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG).

Journal: BMC medicine

Published: February 15, 2025

Prognostic impacts of RHOA G17V mutation in cell-free DNA assessed by droplet digital polymerase chain reaction in patients with angioimmunoblastic T-cell lymphoma.

Prognostic impacts of RHOA G17V mutation in cell-free DNA assessed by droplet digital polymerase chain reaction in patients with angioimmunoblastic T-cell lymphoma.

Journal: British journal of haematology

Published: December 12, 2024

Single-center study of COVID-19 in patients with chronic lymphocytic leukemia

Single-center study of COVID-19 in patients with chronic lymphocytic leukemia

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: December 02, 2024

Clinical and molecular biological characterization of patients with accelerated chronic lymphocytic leukemia

Clinical and molecular biological characterization of patients with accelerated chronic lymphocytic leukemia

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: January 07, 2024

Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience.

Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience.

Journal: Annals of hematology

Published: August 20, 2023

Efficacy and safety of BTK inhibitor, venetoclax and rituximab in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma

Efficacy and safety of BTK inhibitor, venetoclax and rituximab in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: June 25, 2023

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort.

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort.

Journal: Blood cancer journal

Published: May 03, 2023

Efficacy and safety of BTK inhibitor combined with bendamustine and rituximab in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma

Efficacy and safety of BTK inhibitor combined with bendamustine and rituximab in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: March 22, 2023

Showing 1-12 of 23

Last Updated: 09/26/2026